Brief: Vaccinex Reports Phase Ib Keynote B84 Combination Study Of Keytruda And Pepinemab
04/01/2022 14:38
Jan 4 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX REPORTS PHASE IB KEYNOTE B84 COMBINATION STUDY OF
KEYTRUDA AND PEPINEMAB IN PATIENTS PASSES PLANNED INTERIM SAFETY
ANALYSIS
Source text for Eikon: ID:nGNXbygmH0
Further company coverage: VCNX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease